Capecitabine: A review
References (77)
- et al.
Tumor inhibitory effects of a new fluorouracil derivative: 5′-Deoxy-5-fluorouridine
Eur J Cancer
(1980) - et al.
Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer
Eur J Cancer
(1993) - et al.
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated inhuman liver and cancer tissue
Eur J Cancer
(1998) - et al.
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
Ann Oncol
(2003) - et al.
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclosphosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
Ann Oncol
(2001) - et al.
Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with ataxane-containing therapy
Ann Oncol
(2003) - et al.
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracyclineand taxane-pretreated metastatic breast cancer
Eur J Cancer
(2004) - et al.
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy
Am J Kidney Dis
(2002) - et al.
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer
Gynecol Oncol
(2004) - et al.
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: A randomized phase II trial
Ann Oncol
(2003)
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: An intergroup, multicenter, phase II study
Ann Oncol
(2004)
First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
Ann Oncol
(2002)
A phase I and pharmacokinetic study of capecitabine in combina tion with epirubicin and cisplatin in patients with inoperable oesophagogastric adenocarcinoma
Ann Oncol
(2002)
Four decades of continuing innovation with fluorouracil: Current and future approaches to fluorou racil chemoradiation therapy
J Clin Oncol
(2004)
Relationship between fluorouracil systemic exposure and tumor response and patient survival
J Clin Oncol
(1994)
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
J Clin Oncol
(1998)
Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons
Cancer
(1992)
Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
J Clin Oncol
(1998)
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
Cancer Chemother Pharmacol
(2000)
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
J Clin Oncol
(2001)
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
J Clin Oncol
(2001)
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
J Clin Oncol
(1998)
Mechanism of action of fluoropyrimidines: Relevance to the new developments in colorectal cancer chemotherapy
Semin Oncol.
(2000)
Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5′-deoxy-5-fluorocytidine (capecitabine)
Biol Pharm Bull
(1998)
Capecitabine: Preclinical pharmacology studies
Invest New Drugs
(2000)
Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors
Clinical pharmacokinetics of capecitabine
Clin Pharmacokinet
(2001)
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer
Cancer Chemother Pharmacol
(2003)
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients
Clin Cancer Res
(1998)
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug
Invest New Drugs
(1999)
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients
Cancer Chemother Pharmacol
(2002)
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
Clin Cancer Res
(1999)
New systemic frontline treatment for metastatic colorectal carcinoma
Cancer
(2004)
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase IIItrials
Br J Cancer
(2004)
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
J Clin Oncol
(2000)
XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer
J Clin Oncol
(2004)
Phase II study of capecitabine and oxaliplatin in first- and second line treatment of advanced or metastatic colorectal cancer
J Clin Oncol
(2002)
Cited by (561)
An innovative synergistic combination using eudragit-coated galactosylated PLGA-pluronic nanoparticles for addressing colorectal cancer
2024, Journal of Drug Delivery Science and Technology[Translated article] Capecitabine-Induced Focal Acral Pigmentation
2024, Actas Dermo-SifiliograficasIntake and biomarkers of folate and folic acid as determinants of chemotherapy-induced toxicities in patients with colorectal cancer: a cohort study
2024, American Journal of Clinical NutritionUnlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration
2023, European Journal of Medicinal Chemistry
Copyright © 2005 Excerpta Medica, Inc. Published by Elsevier Inc. All rights reserved.